Immunogenicity of yeast-derived hepatitis B vaccine in Pakistani adults

A study of the immunogenicity and safety of 20m recombinant DNA yeast derived hepatitis B vaccine was conducted in 153 Pakistani adults. All participants were in good physical condition had negative hepatitis B serological markers [HbsAg, anti HBs, anti-HBc] and normal ALT. Anti-HBs developed in 33 percent, 81 percent and 98 percent of subjects one month after the first, second and third dose respectively. Minor systemind local side-effects were observed in 30 percent of individuals. We conclude that yeast derived hepatitis B vaccine is safe, effective and immunogenic in Pakistani adults